Skip to main content

LCD L33420: Lab: Bladder/Urothelial Tumor Markers

LCD L33420, Lab: Bladder/Urothelial Tumor Markers, is the Local Coverage Determination that Palmetto GBA applies to claims from 7 states (AL, GA, NC, SC, TN, VA, WV), effective 2021-03-04 and first in force 2015-10-01. The policy text runs 959 words, and its billing and coding article A53095 lists 43 ICD-10-CM codes that support medical necessity for 5 procedure codes. 1 other contractor version share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 43 covered ICD-10-CM codes: 17 fewer codes than L36678 (Noridian Healthcare Solutions, LLC, 60 codes, revised 2025-11-06).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Palmetto GBA
States and territories
7
AL GA NC SC TN VA WV
Revision effective
2021-03-04
Original effective
2015-10-01
Policy text
959 words
Covered ICD-10 codes (articles)
43

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L33420
ContractContractorTypeStates
11201Palmetto GBAA and B and HHH MACSC
11301Palmetto GBAA and B and HHH MACVA
11401Palmetto GBAA and B and HHH MACWV
11501Palmetto GBAA and B and HHH MACNC
11202Palmetto GBAA and B and HHH MACSC
11302Palmetto GBAA and B and HHH MACVA
11402Palmetto GBAA and B and HHH MACWV
11502Palmetto GBAA and B and HHH MACNC
10111Palmetto GBAA and B MACAL
10211Palmetto GBAA and B MACGA
10311Palmetto GBAA and B MACTN
10112Palmetto GBAA and B MACAL
10212Palmetto GBAA and B MACGA
10312Palmetto GBAA and B MACTN

Billing and coding article A53095: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A53095 (Billing and Coding: Lab: Bladder/Urothelial Tumor Markers) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A53095: Billing and Coding: Lab: Bladder/Urothelial Tumor Markers (Billing and Coding, effective 2024-10-01)

Covered ICD-10-CM codes
43
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
5
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A53095
ICD-10-CMDescription (FY2027)
C67.0Malignant neoplasm of trigone of bladder
C67.1Malignant neoplasm of dome of bladder
C67.2Malignant neoplasm of lateral wall of bladder
C67.3Malignant neoplasm of anterior wall of bladder
C67.4Malignant neoplasm of posterior wall of bladder
C67.5Malignant neoplasm of bladder neck
C67.6Malignant neoplasm of ureteric orifice
C67.7Malignant neoplasm of urachus
C67.8Malignant neoplasm of overlapping sites of bladder
C67.9Malignant neoplasm of bladder, unspecified
C7A.010Malignant carcinoid tumor of the duodenum
C7A.011Malignant carcinoid tumor of the jejunum
C7A.012Malignant carcinoid tumor of the ileum
C7A.020Malignant carcinoid tumor of the appendix
C7A.021Malignant carcinoid tumor of the cecum
C7A.022Malignant carcinoid tumor of the ascending colon
C7A.023Malignant carcinoid tumor of the transverse colon
C7A.024Malignant carcinoid tumor of the descending colon
C7A.025Malignant carcinoid tumor of the sigmoid colon
C7A.026Malignant carcinoid tumor of the rectum
C7A.090Malignant carcinoid tumor of the bronchus and lung
C7A.091Malignant carcinoid tumor of the thymus
C7A.092Malignant carcinoid tumor of the stomach
C7A.093Malignant carcinoid tumor of the kidney

Procedure codes: 86294, 86316, 86386, 88120, 88121.

Coverage indications, limitations and medical necessity

INDICATIONS

Gross painless hematuria is often the first manifestation of an urothelial tumor. Since the degree of hematuria bears no relation to the seriousness of the underlying disease, the microscopic finding of blood in the urine is a serious symptom until significant pathology has been excluded.

At this time, there is no published consensus from the following national organizations: National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO), American Urological Association (AUA) and the International Bladder Cancer Consensus Group (IBCCG) regarding the management of persistent asymptomatic microscopic hematuria. Due to insufficient supporting data, the AUA’s 2001 best practices policy could not recommend routine use of voided urinary markers in the evaluation of patients with microscopic hematuria. 3

Recommended surveillance schedules for patients with a previous negative evaluation for unexplained microscopic hematuria include annual urinalysis and voided urinary cytology until the hematuria resolves, or for up to 3 years if microscopic hematuria persists. The AUA has been silent regarding practice guidelines due to the paucity of prevalence studies on asymptomatic microscopic hematuria.

Cystoscopy in conjunction with bladder tumor markers is the standard practice to evaluate patients with symptoms suggesting bladder cancer and to monitor treated patients for recurrence or progression. Although cystoscopy is considered the “gold standard”, studies have shown that up to 20% of tumor can be missed. Urinary cytology has close to a 90%-100% specificity, but only 10%-50% sensitivity for low grade urinary cancer (UC) detection. Due to this deficit, clinicians have sought noninvasive tumor markers detectable in urine.

Upwards of 50% of patients have recurrence of bladder cancer within 5 years.

After initial diagnosis and treatment, patients with UC are frequently monitored every 3 months for the first 2 years, every 4 months for the third, year then usually twice a year for the fourth year. Annual monitoring is recommended during years 5 through 15.

Diagnostic and Surveillance Tests

• BTA TRAK ® - a quantitative determination of human complement factor H-related protein

• Nuclear matrix protein 22 (NMP-22) – detects nuclear mitotic apparatus protein believed to be released during apoptosis; a quantitative assay, which is either positive of negative

• NMP-22 ® BladderChek ® – a CLIA-waved assay, point of care test with an immunochromographic qualitative format taking 20 minutes to perform

• The UroVysion ® Bladder Cancer Kit is fluorescence in situ hybridization (FISH) DNA probe technology. It is designed to detect aneuploidy for chromosomes 3, 7, 17 and loss of the 9p21 locus. This assay involves visualization of nucleic acid sequences within cells by creating short sequences of fluorescently labeled, single-strand DNA probes that match target sequences. The probes bind to complementary strands of DNA to identify the targeted chromosome(s) location. It is used to detect chromosomal abnormalities in voided urine to assist not only in bladder cancer surveillance but also in the initial identification of bladder cancer.

Scientific studies demonstrate the sensitivity of BTA and NMP-22 ® are superior to urinary cytology. 1 Studies affirm the adjunctive value of BTA stat ® and NMP-22 ® in suspected and known bladder cancer in conjunction with cystoscopy. However, false positive results occur more frequently in the presence of hematuria, nephrolithiasis, recent GU instrumentation, inflammation and other urological malignancies. Administration of bacillus Calmette-Guerin (BCG) within 2 years of testing decreases specificity to 28%.

The DNA probe assay has high sensitivity (81%) and specificity (96%) for high grade tumors, but lower sensitivity (36-57%) for low grade and stage tumors. The assay specificity approaches that of cytology, and can be utilized in patients recently treated with intravesical BCG. This can result in a positive UroVysion ® test with a negative study for UC. This assay has also been shown to be useful in predicting tumor recurrence following BCG therapy.

At present the IBCCG has recommended that tumor markers be used in conjunction with cystoscopy. They also concluded that routine screening for bladder cancer is not cost-effective. 3 The US Preventive Services Task Force concluded bladder tumor markers do not have a proven role in screening of asymptomatic patients for early detection of bladder cancer. 3 NCCN, ASCO, and AUA are silent regarding the utilization of these bladder tumor markers.

Surveillance Tests

• BTA (bladder tumor antigen) stat ® - a qualitative CLIA-waved test that identifies a human complement factor H-related protein produced by several human bladder cell lines

• The ImmunoCyt ™ test is cleared for monitoring bladder cancer recurrence only in conjunction with cytology and cystoscopy. The assay uses fluorescent labeled antibodies to 3 markers (carcinoembryonic antigen, and mucins LDQ10 and M344) commonly found on malignant exfoliated urothelial cells. The ImmunoCyt™ assay has also been shown to be more sensitive than urine cytology.

LIMITATIONS

Cystoscopy in conjunction with bladder tumor markers is standard practice to evaluate patients with symptoms suggesting bladder cancer and to monitor treated patients for recurrence or progression. Exceptions, such as high grade bladder cancers s/p radical cystectomy, do exist which preclude cystoscopy prior to testing. Testing indications, limitations and frequency do not apply to urine cytology.

Bladder cancer tumor markers performed by any technology, immunoassay, molecular or FISH testing, are not covered for screening of all patients with hematuria. Bladder tumor markers are not expected to be performed until other diagnostic studies fail to identify the etiology of the hematuria. Urine cytology is not considered a bladder tumor marker.

All other bladder cancer marker assays, including but not limited to the following, regardless of the methodology are considered investigational and not covered by Medicare:

• BCLA-4

• BLCA-1

• Hyaluronic acid

• Hyaluronidase

• Lewis X antigen

• Microsatellite markers

• Quanticyt

• Soluble FAS TATI (tumor associated trypsin inhibitor)

• Soluble e-cadherin

• Survivin

• Telomerase

• UBC ™ Rapid Test (urinary bladder cancer test for cytokeratins 8 and 18)

Summary of evidence (opening)

N/A

The contractor cites 5 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2015-10-01
Current revision effective
2021-03-04
Last reviewed by the contractor
2021-01-13
MCD version
41
Derived from
L32118

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Palmetto GBA hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L33420 cover?

Gross painless hematuria is often the first manifestation of an urothelial tumor. Since the degree of hematuria bears no relation to the seriousness of the underlying disease, the microscopic finding of blood in the urine is a serious symptom until significant pathology has been excluded. The full 959-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L33420 apply to?

Palmetto GBA applies it to Medicare claims in 7 states: AL, GA, NC, SC, TN, VA, WV. It binds only that contractor; 1 other contractor version of this title governs other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L33420?

The companion billing and coding article A53095 lists 43 ICD-10-CM codes in 1 group that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L33420?

A denial under LCD L33420 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A53095's 43 covered diagnosis codes, then file a redetermination with Palmetto GBA within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.